Submitted by Anonymous (not verified) on 22 September 2023 - 12:27
Human medicines European public assessment report (EPAR): Imjudo, tremelimumab, Carcinoma, Hepatocellular, Date of authorisation: 20/02/2023, Revision: 2, Status: Authorised
Source: